144 related articles for article (PubMed ID: 32967493)
1. Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
Cortes JE; Candoni A; Clark RE; Leber B; Montesinos P; Vyas P; Zeidan AM; Heuser M
Leuk Lymphoma; 2020 Dec; 61(14):3287-3305. PubMed ID: 32967493
[TBL] [Abstract][Full Text] [Related]
2. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
[TBL] [Abstract][Full Text] [Related]
3. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
Relias V; McBride A; Newman MJ; Paul S; Saneeymehri S; Stanislaus G; Tobin J; Hoang CJ; Ryan JC; Galinsky I
J Oncol Pharm Pract; 2021 Apr; 27(3):658-672. PubMed ID: 33215562
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cortes JE; Heidel FH; Hellmann A; Fiedler W; Smith BD; Robak T; Montesinos P; Pollyea DA; DesJardins P; Ottmann O; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Heuser M
Leukemia; 2019 Feb; 33(2):379-389. PubMed ID: 30555165
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada.
Hu Y; Charaan M; van Oostrum I; Heeg B; Bell T
J Med Econ; 2021; 24(1):150-161. PubMed ID: 33461352
[TBL] [Abstract][Full Text] [Related]
9. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
Goldsmith SR; Lovell AR; Schroeder MA
Drugs Today (Barc); 2019 Sep; 55(9):545-562. PubMed ID: 31584572
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia.
Tremblay G; Daniele P; Bell T; Chan G; Brown A; Cappelleri JC
J Comp Eff Res; 2021 May; 10(7):603-612. PubMed ID: 33733815
[No Abstract] [Full Text] [Related]
11. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
Norsworthy KJ; By K; Subramaniam S; Zhuang L; Del Valle PL; Przepiorka D; Shen YL; Sheth CM; Liu C; Leong R; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Oct; 25(20):6021-6025. PubMed ID: 31064779
[TBL] [Abstract][Full Text] [Related]
12. Glasdegib in the treatment of acute myeloid leukemia.
Wolska-Washer A; Robak T
Future Oncol; 2019 Oct; 15(28):3219-3232. PubMed ID: 31432695
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of glasdegib for the treatment of acute myelogenous leukemia.
Thomas X; Heiblig M
Expert Opin Pharmacother; 2020 Apr; 21(5):523-530. PubMed ID: 32027196
[No Abstract] [Full Text] [Related]
14. Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.
Feld J; Silverman LR; Navada SC
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e415-e422. PubMed ID: 33547022
[TBL] [Abstract][Full Text] [Related]
15. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
Cortes JE; Dombret H; Merchant A; Tauchi T; DiRienzo CG; Sleight B; Zhang X; Leip EP; Shaik N; Bell T; Chan G; Sekeres MA
Future Oncol; 2019 Nov; 15(31):3531-3545. PubMed ID: 31516032
[TBL] [Abstract][Full Text] [Related]
16. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Cortes JE; Douglas Smith B; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Sekeres MA; Robak T; Ma WW; Zeremski M; Naveed Shaik M; Douglas Laird A; O'Connell A; Chan G; Schroeder MA
Am J Hematol; 2018 Nov; 93(11):1301-1310. PubMed ID: 30074259
[TBL] [Abstract][Full Text] [Related]
17. Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
[TBL] [Abstract][Full Text] [Related]
18. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
19. Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
Zucenka A; Maneikis K; Pugaciute B; Ringeleviciute U; Dapkeviciute A; Davainis L; Daukelaite G; Burzdikaite P; Staras V; Griskevicius L
Ann Hematol; 2021 May; 100(5):1195-1202. PubMed ID: 33661333
[TBL] [Abstract][Full Text] [Related]
20. Glasdegib in newly diagnosed acute myeloid leukemia.
Sarkaria SM; Heaney ML
Expert Rev Anticancer Ther; 2021 Jun; 21(6):573-581. PubMed ID: 33593233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
